J. Sullivan-Bolyai

发表

FV‐100 versus valacyclovir for the prevention of post‐herpetic neuralgia and the treatment of acute herpes zoster‐associated pain: A randomized‐controlled trial

S. Tyring, A. Moore, Patricia C. Lee, 2016, Journal of medical virology.

Blocking Borrelia burgdorferi transmission from infected ticks to non-human primates with a human monoclonal antibody.

M. Klempner, Colby A. Souders, L. Cavacini, 2021, The Journal of clinical investigation.

Rapid Decline of Viral RNA in Chronic Hepatitis C Patients Treated Once Daily with IDX320: A Novel Macrocyclic HCV Protease Inhibitor

K. Simon, C. Weegink, H. Reesink, 2012, Antiviral therapy.

Guillain-Barre syndrome after administration of killed vaccines.

L. Schonberger, G. Noble, J. Sullivan-Bolyai, 1977, Developments in biological standardization.

Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

D. Asmuth, H. Vargas, J. McCarville, 2012, Antimicrobial Agents and Chemotherapy.

Seroepidemiology of varicella.

J. Sullivan-Bolyai, S. Niku, R. Muench, 1986, The Journal of infectious diseases.

Occupational risk of HIV, HBV and HSV-2 infections in health care personnel caring for AIDS patients.

J. Cherry, J. Sullivan-Bolyai, A. Garakian, 1988, American journal of public health.

Poliomyelitis in the United States

L. Schonberger, J. Sullivan-Bolyai, J. Bryan, 1943, Nature.

Impact of chickenpox on households of healthy children

J. Sullivan-Bolyai, A. Marchand, P. Cox, 1987, The Pediatric infectious disease journal.

AIDS wasting syndrome: A persisting problem in the protease-Inhibitor era

J. Sullivan-Bolyai, C. Bell, 1997 .

Incidence of Neonatal Herpes Simplex Infections-Reply

H. Hull, L. Corey, Christopher B Wilson, 1985 .

Neonatal Herpes Simplex Virus Infection in King County, Washington: Increasing Incidence and Epidemiologic Correlates

H. Hull, L. Corey, Christopher B Wilson, 1983 .

Disseminated neonatal herpes simplex virus type 1 from a maternal breast lesion.

L. Corey, R. Jacobs, K. Fife, 1983, Pediatrics.

Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects

D. Mayers, J. Sullivan-Bolyai, Xiao-jian Zhou, 2010, Antimicrobial Agents and Chemotherapy.

Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy.

H. Hull, L. Corey, A. Smith, 1986, Pediatric infectious disease.

Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery.

P. D. del Nido, S. Levitsky, K. Rodvold, 1993, The Pediatric infectious disease journal.

Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 study

M. Lai, J. Yeon, T. Chen, 2006 .

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

D. Mayers, J. Lalezari, E. Dejesus, 2010 .

966 IDX184, A LIVER-TARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR: RESULTS OF A FIRST-IN-MAN SAFETY AND PHARMACOKINETIC STUDY

D. Mayers, J. Sullivan-Bolyai, B. Belanger, 2009 .

36 Pharmacokinetics and pharmacodynamics of pradefovir, a liver-targeting prodrug of PMEA in HBV patients

J. Sullivan-Bolyai, L. Yeh, Y. Xu, 2006 .

Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis C

P. Kwo, W. O'Riordan, J. McCarville, 2013, Antiviral therapy.

First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

X. J. Zhou, H. Reesink, D. Mayers, 2012, Antimicrobial Agents and Chemotherapy.

Risk factors for Guillain‐Barré syndrome

R. Holman, R. Kaslow, L. Schonberger, 1987, Neurology.

A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis

Todd G. Smith, M. Klempner, Yang Wang, 2022, Scientific Reports.

Reye's syndrome in the United States in 1977-1978, a non-influenza B virus year.

D. Morens, L. Schonberger, J. Sullivan-Bolyai, 1979, The Journal of infectious diseases.

Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977.

J A Bryan, L. Schonberger, D J Bregman, 1979, American journal of epidemiology.

Epidemiology of Reye syndrome.

L. Corey, J. Sullivan-Bolyai, 1981, Epidemiologic reviews.

Occupational risk of HIV, HBV and HSV-2 infections in health care personnel caring for AIDS patients

J. Cherry, J. Sullivan-Bolyai, A. Garakian, 1987 .

Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects

D. Mayers, J. Sullivan-Bolyai, B. Belanger, 2009, Antimicrobial Agents and Chemotherapy.

Aflatoxin and Reye's syndrome: a case control study.

D. Morens, J. Sullivan-Bolyai, D. Nelson, 1980, Pediatrics.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

L. Webster, W. O'Riordan, E. Lawitz, 2014, Journal of hepatology.

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.

L. Webster, W. O'Riordan, E. Lawitz, 2014, Journal of hepatology.

O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy

M. Buti, X. Forns, A. Howe, 2015 .

HLA antigens in Guillain‐Barré Syndrome

R. Kaslow, L. Schonberger, J. Sullivan-Bolyai, 1984, Neurology.

Hyperpyrexia due to air-conditioning failure in a nursing home.

J. Sullivan-Bolyai, D. Bregman, J. Howell, 1979, Public health reports.